Comparison of [18F] PSMA-1007 PET/CT and Conventional Imaging in the Detection of Metastatic Clear Cell Renal Cell Carcinoma

What this Trial Is About

Researchers are evaluating the use of a new imaging technique called [18F] PSMA-1007 PET/CT to detect metastatic clear cell renal cell carcinoma, a type of kidney cancer. This study focuses on patients 18 years or older who have metastatic clear cell kidney cancer and have not yet received systemic therapy. The goal is to see if this PET imaging can identify additional metastatic sites that conventional CT or MRI scans might miss, potentially changing how the disease is managed. All participants will undergo a single [18F] PSMA-1007 PET/CT scan to evaluate metastatic cancer lesions. This is a prospective, open-label study conducted at a single institution. Participants must have baseline conventional imaging of the chest, abdomen, and pelvis within 5 weeks before enrollment. The study will compare the PET/CT results to those of conventional imaging to assess the number of metastatic lesions and any changes in treatment plans. During the study, participants will have their imaging results reviewed, and any necessary histologic confirmation by biopsy will be performed if metastatic disease is found on conventional imaging. Researchers will monitor the number of detected metastatic lesions and any changes in patient management within one month. Pathologic correlates will also be assessed when applicable. The study expects to follow patients until September 2025, with careful safety and outcome monitoring throughout the process.

[18F] PSMA-1007 PET/CT in Metastatic Clear Cell Renal Cell Carcinoma